Blog Big Molecule Watch March 20, 2018

Novartis Sues Regeneron Regarding EYLEA® (aflibercept) and ZALTRAP® (aflibercept)

On March 19, 2018, Novartis and Grifols sued Regeneron in the Southern District of New York, asserting that Regeneron’s manufacture of its EYLEA® and ZALTRAP® products infringes U.S. Patent No. 5,688,688. Previous cases in which Novartis asserted the ’688 patent against MedImmune, Biogen, and Alexion have all been concluded.

The post Novartis Sues Regeneron Regarding EYLEA® (aflibercept) and ZALTRAP® (aflibercept) appeared first on Big Molecule Watch.